SCHEMBL7544500

SCHEMBL7544500

Cn1cc(CSC(=O)c2ccccc2)cn1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
OPRM1 P35372 4/20 0.39
OPRK1 P41145 2/20 0.39
KMT2A Q03164 2/20 0.39
JAK2 O60674 1/20 0.39
JAK1 P23458 1/20 0.39
JAK3 P52333 1/20 0.39
LMNA P02545 1/20 0.39
HPGD P15428 1/20 0.39
HDAC1 Q13547 1/20 0.38
SMN1; SMN2 Q16637 3/20 0.37
RAB9A P51151 1/20 0.37
HDAC3 O15379 1/20 0.37
HDAC4 P56524 1/20 0.37
HDAC7 Q8WUI4 1/20 0.37
HDAC8 Q9BY41 1/20 0.37
HDAC9 Q9UKV0 1/20 0.37
HDAC5 Q9UQL6 1/20 0.37
ALDH1A1 P00352 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7537847 0.78 KMT2A (0.33) KMT2AALDH1A1GPR139
SCHEMBL10680972 0.78 ALDH1A1 (0.41) MAPK1L3MBTL1OPRM1OPRK1KMT2A
Tibenzate SCHEMBL2110094 0.75 IDO1 (0.52) L3MBTL1KMT2ALMNAHDAC1SMN1; SMN2
SCHEMBL15570529 0.73 SMN1; SMN2 (0.59) MAPK1L3MBTL1KMT2ALMNAHPGD
SCHEMBL9735929 0.72 OPRM1 (0.44) MAPK1L3MBTL1OPRM1OPRK1JAK2
SCHEMBL28460668 0.71 IDO1 (0.52) L3MBTL1KMT2ALMNAHPGDHDAC1
SCHEMBL1479171 0.71 NAPRT (0.53) KMT2ALMNASMN1; SMN2RAB9AALDH1A1
SCHEMBL7547678 0.71 HPGDS (0.40) MAPK1KMT2AHDAC1HDAC3HDAC4
SCHEMBL5702311 0.69 ALDH1A1 (0.52) L3MBTL1KMT2ALMNAHPGDHDAC1
SCHEMBL28463445 0.69 IDO1 (0.58) L3MBTL1KMT2ALMNARAB9AFNTA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6468995-B1 ANTIBIOTICS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-10-22 US disclosed
EP-0667868-B1 CEPHEM COMPOUNDS FUJISAWA PHARMACEUTICAL CO (JP) 2002-05-15 EP disclosed
US-20010056089-A1 Novel crystal of cephalosporin compound FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-12-27 US disclosed
US-20010007903-A1 NOVEL CRYSTAL OF CEPHALOSPORIN COMPOUND FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-07-12 US disclosed
EP-0780393-A1 NOVEL CRYSTAL OF CEPHALOSPORIN COMPOUND FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1997-06-25 EP disclosed
CN-1116425-A New cephem compounds FUJISAWA PHARMACEUTICAL CO (JP) 1996-02-07 CN disclosed
EP-0667868-A1 NEW CEPHEM COMPOUNDS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1995-08-23 EP disclosed
WO-1995007283-A1 NEW CEPHEM COMPOUNDS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1995-03-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010056089-A1 Novel crystal of cephalosporin compound CEP170, CXXC4, DAO MAPK1 2697/4885L3MBTL1 4138/4885OPRM1 3136/4885
US-20010007903-A1 NOVEL CRYSTAL OF CEPHALOSPORIN COMPOUND CEP170, CXXC4, DAO MAPK1 2697/4885L3MBTL1 4138/4885OPRM1 3136/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.